



## Solenio Therapeutics Announces Presentations at ENDO 2022

June 7, 2022 12:00 PM EDT

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA.

Details of the presentations are as follows:

### 2022 Endocrine Society Meeting (ENDO)

Title: *Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome*  
Format: Oral Presentation  
Presenter: Dr. Eric Felner on behalf of the DESTINY PWS Investigators and Soleno Therapeutics  
Date: Sunday, June 12, 2022  
Time: 11 AM to 12:30 PM Eastern Time

Title: *Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome*  
Format: Poster  
Presenter: Dr. Michael Woloschak on behalf of the DESTINY PWS Investigators and Soleno Therapeutics  
Date: Sunday, June 12, 2022  
Time: 1:00 PM ET

The copy of the presentation materials will be available in the Investors section on the Company's website at [www.solenio.life](http://www.solenio.life) after presentation at the meeting.

### About Soleno Therapeutics, Inc.

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit [www.solenio.life](http://www.solenio.life).

**Corporate Contact:**  
Brian Ritchie  
LifeSci Advisors, LLC  
212-915-2578



Source: Soleno Therapeutics